Head-to-head evidence
NNC0662-0419 vs UBT251
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP/glucagon receptor (triple) · full Obesity pipeline
NNC0662-0419
Developed by Novo Nordisk
NCT06737536 · Phase 1 · completed
Participants were randomly assigned to drug or placebo under double-blind conditions across ascending-dose cohorts, a sound early-safety design, but the primary measure was the number of adverse events rather than a weight or clinical outcome, and results have not yet been reported.
Next expected readout: December 2026 · NCT07184632 (registry estimate)
UBT251
Developed by Novo Nordisk under a licence from United Bio-Technology (Hengqin)
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2027 · NCT07395687 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: NNC0662-0419's landscape · UBT251's landscape